Measuring The Global Biomedical Pulse: The Biopharmaceutical Investment & Competitiveness (BCI) Survey – 2015

Meir Perez Pugatch, David Torstensson , Rachel Chu

Research output: Book/ReportReport

Abstract

Investment in biomedical innovation today represents one of the most high value areas of investment economies can secure. In 2014 global life sciences R&D spending was estimated at around $200 billion, with investment by leading research-based biopharmaceutical companies at over a quarter of this figure. Today, economies seeking to attract biomedical investment are competing on a global scale, with developed and emerging economies vying for this investment side by side. But how do governments and economies improve their competitiveness and secure a larger piece of global biomedical investment? A growing body of data suggests that on top of market size, demand and costs, economies’ competitiveness for biomedical investment is positively linked to the local policy environment – all of the laws, regulations and initiatives in place affecting biopharmaceuticals. Thus, for developed and emerging economies alike that have targeted biomedical investment as being of strategic importance to national economic development and growth, there is a pressing need to understand and map the state of the biomedical investment environment in a given economy.
Original languageEnglish
Place of PublicationWashington DC
PublisherPugatch Consilium
Commissioning body PhRMA
Number of pages86
Edition2
StatePublished - 2015

Fingerprint

Dive into the research topics of 'Measuring The Global Biomedical Pulse: The Biopharmaceutical Investment & Competitiveness (BCI) Survey – 2015'. Together they form a unique fingerprint.

Cite this